LISATA THERAPEUTICS, INC. — Director's Dealing 2018

Apr 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2018-04-06

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-06	Performance Rights	$	A	33300	Acquired		Common Stock (33300)	Direct

Footnotes

F1: Each performance right represents a contingent right to receive one share of common stock of the Issuer.

F2: The performance criteria was satisfied on April 6, 2018 and the performance right shall vest in full on the date of stockholder approval of a new or amended equity plan provided that such approval is obtained on or prior to August 30, 2018 and if not obtained by such date this performance right shall terminate (the "Vesting Date").